Biosimilar new entry was expected to shake up the pharmaceuticals market, leading to lower prices and increased access to drugs. However, market access has been slower than many predicted, with some citing concerns around anti-competitive practices limiting entry and expansion. This is reflected in the European Commission DG Competition’s 2021 Management Plan, which anticipates that the Commission will continue investigating anti-competitive practices that lead to delays in the entry of biosimilars and generics.

In this edition of Raising the Bar, Matt Tavantzis and I explore the economic benefits from biosimilar competition and consider both demand and supply-side factors that might be limiting growth.